Suppr超能文献

无皮质类固醇免疫抑制的心脏移植:长期结果

Cardiac transplantation with corticosteroid-free immunosuppression: long-term results.

作者信息

Lee K F, Pierce J D, Hess M L, Hastillo A K, Wechsler A S, Guerraty A J

机构信息

Department of Surgery, Medical College of Virginia-Virginia Commonwealth University, Richmond 23298.

出版信息

Ann Thorac Surg. 1991 Aug;52(2):211-7; discussion 218. doi: 10.1016/0003-4975(91)91338-v.

Abstract

To assess the long-term safety of an immunosuppressive regimen without corticosteroids, we retrospectively evaluated 42 long-term (greater than 1 year) survivors of orthotopic cardiac transplantation. We determined the incidence of (1) conversion of the immunosuppressive regimen from cyclosporine and azathioprine alone (group I) to cyclosporine, azathioprine, and prednisone (group II), (2) late acute graft rejection (defined as occurring at greater than 1 postoperative year), and (3) major postoperative complications related to corticosteroids. Of the 42 patients who were started on cyclosporine and azathioprine, 48% remained in group I, and 52% converted to group II. Forty-five percent of group II patients were able to taper and discontinue prednisone in 15.6 +/- 2.2 months. Among the patients on long-term corticosteroid-free immunosuppression, the incidence of late rejection was 2.1% per endomyocardial biopsy. The incidence of late infectious episodes was not significantly different between the two groups of patients, although diabetes mellitus and hypercholesterolemia were more prevalent in group II than in group I. These data suggest that cardiac transplant recipients who chronically remain on corticosteroid-free immunosuppression represent a select group of patients with an acceptably low risk of late graft rejection and associated reduction of potential risk factors of accelerated coronary artery disease.

摘要

为评估无皮质类固醇免疫抑制方案的长期安全性,我们回顾性评估了42例原位心脏移植的长期(超过1年)存活者。我们确定了以下情况的发生率:(1)免疫抑制方案从仅使用环孢素和硫唑嘌呤(I组)转换为环孢素、硫唑嘌呤和泼尼松(II组);(2)晚期急性移植物排斥反应(定义为术后1年以上发生);(3)与皮质类固醇相关的主要术后并发症。在开始使用环孢素和硫唑嘌呤的42例患者中,48%仍在I组,52%转换至II组。II组中45%的患者能够在15.6±2.2个月内逐渐减少并停用泼尼松。在长期无皮质类固醇免疫抑制的患者中,每例心内膜心肌活检的晚期排斥反应发生率为2.1%。两组患者晚期感染事件的发生率无显著差异,尽管II组中糖尿病和高胆固醇血症比I组更常见。这些数据表明,长期维持无皮质类固醇免疫抑制的心脏移植受者是一组晚期移植物排斥反应风险可接受且潜在加速冠状动脉疾病风险因素相关降低的特定患者群体。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验